More than 10 million people worldwide are suffering from Parkinson’s disease¹. The available therapies are largely symptomatic and there are no truly disease modifying treatment options available as yet that can protect the loss of dopamine producing neurons.

SCC - 138, is a potent, orally active, and exhibits superior safety / tolerability profile. In MPTP mouse model SCC - 138 protects the loss of the dopamine-producing neurons.

SPARC initiated a double blind, randomized, placebo controlled, multiple dose, phase 1 study of SCC - 138 in patients with PD patients. Till date, we have completed 6 dose escalations and have not observed significant adverse events in the Parkinson’s Disease population. Preliminary pharmacokinetic data indicate the presence of drug in the CSF suggesting that the drug is able to get to its site of intended action. We are planning to initiate a proof of concept study in Q3 FY19.